It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Discover precise insights into brain neurochemistry with Sygnature Discovery's in vivo microdialysis and cOFM services. With over 20 years of expertise, we design bespoke studies that reveal how compounds modulate neurotransmitter systems in health and disease. Using UHPLC/HPLC with electrochemical detection or mass spectrometry, we deliver robust PK/PD data to support confident CNS decision making.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesized and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesized and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Using Design of Experiments to Increase Protein Yield in HEK293-6E Cells
HEK293 6E cells (which we have on license from the National Research Council (NRC) in Canada) are a well-established mammalian expression system used in the protein expression team at Sygnature Discovery for expressing recombinant proteins. In this case study Sarah Beck describes the experiments that Calum Wilson our summer intern student performed under her guidance, that aimed to improve our standard HEK cell culture protocols. Calum carried out a Design of Experiments (DoE) study to investigate transfection conditions and feeding regimes in HEK293 6E cells with the overall aim being to optimize yields of recombinant protein.
Which variables were investigated?
Cell density at transfection, DNA concentration, DNA:PEI ratio, and feeding regimes were the variable studied. Two of these were categorical factors so we were unable to use a definitive screening design. Instead, a custom design was created in the JMP software that still allowed us to investigate 2-way factor interactions in two blocks of 12 runs, with each block including a control with our current culture conditions. In total twenty-four different 50ml cultures of HEK293 6E cells were performed with cell viability and mCherry protein expression levels compared as the output for each condition tested. The data obtained was statistically analyzed with the JMP software.
Interpretation of DoE data
Analysis of DoE data for mCherry yield showed the interaction of DNA:PEI ratio and DNA concentration together had more of a significant effect (P value < 0.05) than individual variables on their own (Figure 1). It was proven to be a good model with R-squared value of 0.91, suggesting that 91% of the observed variation could be explained by the model generated by the software. Using the prediction profiler tool in JMP showed the optimal settings for each of the factors for highest mCherry yield. These conditions were matched by the analysis of the cell viability output (data not shown). e optimal conditions for highest mCherry yield.
Figure 1: Logworth analysis of DoE data for mCherry yield
Confirmation Run: Testing the predicted optimal conditions in HEK cell transfections
A confirmation run was then performed with the new predicted optimal settings from the DoE for each of the factors. mCherry transfections in HEK cells were tested and compared to standard (original) conditions (Figure 2). It was found that the new optimal conditions produced a higher, 80% improved, mCherry yield and these cells also had a higher percentage cell viability at harvest compared to our standard conditions.
Figure 2: mCherry yield at harvest for HEK cells transfected in standard conditions versus optimal conditions.
Conclusion
This Design of Experiments (DoE) study was a rapid way to investigate four variables to increase protein yield in our HEK293 6E mammalian expression system. Optimal conditions were identified which successfully improved mCherry yield by 80%. These also included using a lower cell density and DNA concentration at transfection which is advantageous in terms of consumption of materials. Design of experiments is a hugely powerful tool and will be extended to optimize other cell culture protocols in use at Sygnature Discovery.
Applying DoE for your projects
As discussed, we can apply DoE variable testing to optimise cell growth. We have also use this to optimise a client protein purification protocol. If you have a protein expression and purification project that you think would benefit from a DoE approach, then please don’t hesitate to get in touch with via the link at the bottom of this page.